# Systemic-first management of HER2-positive brain metastases

Source: https://onco.cc/ideas/idea-cns-first-adc-strategy/  
OnCo record `idea-cns-first-adc-strategy` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

With Enhertu and tucatinib controlling brain metastases in most patients, radiation could be reserved for those who do not respond, sparing cognitive side effects.

## Summary

This idea would manage asymptomatic or small HER2-positive brain metastases with systemic therapy first, trastuzumab deruxtecan or the tucatinib triplet, holding stereotactic radiosurgery in reserve for lesions that do not respond. Radiation necrosis and cognitive decline are cumulative, whereas DESTINY-Breast12 and HER2CLIMB show systemic agents now achieve intracranial responses comparable to local therapy in many patients. The hypothesis is that systemic-first treatment with deferred radiosurgery is non-inferior on intracranial progression-free survival and superior on neurocognitive outcomes. The test is a randomised trial of upfront versus deferred radiosurgery with neurocognitive function at one year as primary endpoint, addressing the brain-delivery bottleneck.

## Fields

- Kind: Idea
- Last checked: 2026-09-07
- Hypothesis: Systemic-first therapy (T-DXd or tucatinib triplet) with deferred radiosurgery is non-inferior to upfront radiosurgery on intracranial PFS and superior on neurocognitive outcomes.
- Rationale: Radiation necrosis and cognitive decline are cumulative; systemic agents now achieve intracranial responses comparable to local therapy in many patients.
- Proposed test: Randomised trial of upfront SRS vs deferred SRS with systemic HER2 therapy; primary endpoint neurocognitive function at 12 months, secondary intracranial PFS and OS.
- Maturity: early-clinical

## Sources

- ClinicalTrials.gov NCT04739761: DESTINY-Breast12: https://clinicaltrials.gov/study/NCT04739761
- ClinicalTrials.gov NCT02614794: HER2CLIMB: https://clinicaltrials.gov/study/NCT02614794

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HER2-positive breast cancer with brain metastases](https://onco.cc/cancers/her2-positive-breast-brain-metastases/)
- technologies: [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- drugs: [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [Tucatinib](https://onco.cc/drugs/tucatinib/)
- terms: [HER2-positive brain metastases](https://onco.cc/terms/her2-brain-metastases/)
- trials: [DESTINY-Breast12](https://onco.cc/trials/destiny-breast12/), [HER2CLIMB](https://onco.cc/trials/her2climb/)
- key papers: [HER2CLIMB brain metastases analysis: intracranial efficacy and survival with tucatinib](https://onco.cc/key-papers/paper-her2climb-brain-lin-jco-2020/), [Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer](https://onco.cc/key-papers/paper-trastuzumab-deruxtecan-breast-her2-positive-n-engl-j-med-2020/), [TUXEDO-1: trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastases](https://onco.cc/key-papers/paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022/)
- bottlenecks: [The brain: barrier and sanctuary](https://onco.cc/bottlenecks/b-brain-delivery/)

---
JSON: https://onco.cc/api/v1/entities/idea-cns-first-adc-strategy.json